Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Recursion Pharmaceuticals
(NASDAQ:RXRX)
Intraday
$8.26
0.14
[1.72%]
After-Hours
$8.26
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$8.26
0.14
[1.72%]
At close: Apr 29
$8.26
0
[0.00%]
PreMarket: 9:09AM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Recursion Pharmaceuticals Stock (NASDAQ:RXRX)
Recursion Pharmaceuticals Stock (NASDAQ: RXRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 26, 2024
Recursion Pharmaceuticals's Options Frenzy: What You Need to Know
Benzinga Insights
-
2 days ago
Wednesday, April 24, 2024
Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner'
Avi Kapoor
-
5 days ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
5 days ago
Thursday, April 11, 2024
Cathie Wood's Ark Invest Sells $20M+ Coinbase Shares As Bitcoin Trades Over $70K, Buys Palantir, Sells Nvidia Stock
Benzinga Neuro
-
Apr 11, 2024, 10:54PM
Tuesday, April 09, 2024
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
Benzinga Insights
-
Apr 9, 2024, 10:00AM
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Benzinga Newsdesk
-
Apr 9, 2024, 6:20AM
Tuesday, March 26, 2024
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares
Benzinga Neuro
-
Mar 26, 2024, 10:30PM
Monday, March 25, 2024
Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships
Anusuya Lahiri
-
Mar 25, 2024, 11:31AM
Monday, March 18, 2024
New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence
Caleb Naysmith
-
Mar 18, 2024, 11:00AM
Wednesday, March 13, 2024
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Mar 13, 2024, 1:18PM
Monday, March 11, 2024
Nvidia's Secret Weapon Is Not Just Chips But Investing $1.5B In AI's Rising Stars: Report Unveils CEO Jensen Huang's 10-Year Vision
Shanthi Rexaline
-
Mar 11, 2024, 8:42AM
Recursion Announces Plans To Open New Office In London In June 2024
Benzinga Newsdesk
-
Mar 11, 2024, 4:40AM
Monday, March 04, 2024
Forecasting The Future: 4 Analyst Projections For Recursion Pharmaceuticals
Benzinga Insights
-
Mar 4, 2024, 8:02AM
Keybanc Maintains Overweight on Recursion Pharmaceuticals, Raises Price Target to $16
Benzinga Newsdesk
-
Mar 4, 2024, 6:32AM
Wednesday, February 28, 2024
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Feb 28, 2024, 2:02PM
Recursion Pharmaceuticals Stock Is Sliding Wednesday: What's Going On?
Adam Eckert
-
Feb 28, 2024, 9:32AM
Recursion Pharmaceuticals shares are trading lower after the company reported mixed Q4 financial results.
Benzinga Newsdesk
-
Feb 28, 2024, 8:28AM
Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Feb 28, 2024, 8:24AM
3D Systems Posts Downbeat Q4 Results, Joins Eventbrite, Lemonade And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Avi Kapoor
-
Feb 28, 2024, 6:23AM
Needham Maintains Buy on Recursion Pharmaceuticals, Raises Price Target to $17
Benzinga Newsdesk
-
Feb 28, 2024, 5:44AM
Tuesday, February 27, 2024
What's Going On With Recursion Pharmaceuticals Stock Tuesday?
Adam Eckert
-
Feb 27, 2024, 5:17PM
Recursion Pharmaceuticals shares are trading lower after the company reported mixed Q4 financial results.
Benzinga Newsdesk
-
Feb 27, 2024, 4:39PM
Recursion Pharmaceuticals Q4 2023 GAAP EPS $(0.42) Beats $(0.44) Estimate, Sales $10.89M Miss $20.35M Estimate
Benzinga Newsdesk
-
Feb 27, 2024, 4:37PM
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Feb 27, 2024, 4:31PM
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Thursday, February 22, 2024
10+ Stocks, ETFs To Ride On Nvidia's Record-Breaking Success
Natan Ponieman
-
Feb 22, 2024, 4:43PM
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Feb 22, 2024, 1:37PM
Wednesday, February 21, 2024
NVIDIA Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Avi Kapoor
-
Feb 21, 2024, 10:07AM
Thursday, February 15, 2024
What's Going On With Recursion Pharmaceuticals Stock On Thursday?
Vandana Singh
-
Feb 15, 2024, 10:03AM
Recursion Pharmaceuticals shares are trading higher after Nvidia reported a 7.706 million share stake in the company.
Benzinga Newsdesk
-
Feb 15, 2024, 9:02AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Feb 15, 2024, 8:05AM
Nvidia Bolsters AI Leadership with Investment in Arm Holdings, Eyes Future Growth in Semiconductor Industry
Anusuya Lahiri
-
Feb 15, 2024, 8:05AM
Wednesday, February 14, 2024
Nvidia Reports 7.706M Share Stake In Recursion Pharmaceuticals
Benzinga Newsdesk
-
Feb 14, 2024, 5:00PM
Wednesday, February 07, 2024
Cathie Wood's Ark Invest Sheds $2.8M Worth Of Nvidia Shares Amid AI Hype, Picks Up Robinhood Stock Worth $1.3M
Benzinga Neuro
-
Feb 7, 2024, 10:20PM
Friday, January 26, 2024
TD Cowen Initiates Coverage On Recursion Pharmaceuticals with Market Perform Rating
Benzinga Newsdesk
-
Jan 26, 2024, 11:35AM
Thursday, January 18, 2024
Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares
Benzinga Neuro
-
Jan 17, 2024, 11:09PM
Wednesday, January 17, 2024
A Glimpse Into The Expert Outlook On Recursion Pharmaceuticals Through 4 Analysts
Benzinga Insights
-
Jan 17, 2024, 7:00AM
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk
-
Jan 17, 2024, 6:18AM
Tuesday, January 16, 2024
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $15 Price Target
Benzinga Newsdesk
-
Jan 16, 2024, 7:15AM
Monday, January 15, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Jan 15, 2024, 12:35PM
Tuesday, January 09, 2024
What's Going On With Recursion Pharmaceuticals Stock?
Erica Kollmann
-
Jan 9, 2024, 12:53PM
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
-
Jan 9, 2024, 10:59AM
Monday, January 08, 2024
Recursion Unveils LOWE Drug Discovery Software Designed To Perform Complex Drug Discovery Tasks Using A Natural Language Interface
Benzinga Newsdesk
-
Jan 8, 2024, 11:06AM
Thursday, January 04, 2024
Recursion Pharmaceuticals shares are trading higher after the company announced it signed an agreement with Bayer AG to in-license a new chemical entity that emerged from its fibrosis research collaboration.
Benzinga Newsdesk
-
Jan 4, 2024, 10:42AM
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
Jan 4, 2024, 10:12AM
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases To Late Discovery Pipeline; Signed An Agreement With Bayer AG To In-License A New Chemical Entity That Emerged From The Companies' Fibrosis Research Collaboration
Benzinga Newsdesk
-
Jan 4, 2024, 8:01AM
Tuesday, January 02, 2024
Cathie Wood's Ark Invest Purchases Nearly $17M Worth Of Roku Shares, Sells Coinbase, Robinhood Stock
Benzinga Neuro
-
Jan 2, 2024, 9:54PM
Monday, January 01, 2024
Peering Into Recursion Pharmaceuticals's Recent Short Interest
Benzinga Insights
-
Jan 1, 2024, 8:15AM
Wednesday, December 20, 2023
Recursion Announced Its Partnership With Enamine To Generate Screening Libraries With Insights From Recursion's Protein-Ligand Interaction Predictions Spanning Across Enamine's Library Of 36 Billion Compounds
Benzinga Newsdesk
-
Dec 20, 2023, 8:01AM
Wednesday, December 06, 2023
Looking Into Recursion Pharmaceuticals's Recent Short Interest
Benzinga Insights
-
Dec 6, 2023, 11:45AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch